Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.39 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.39 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.39 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.39 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.38 |
| ▸ | TSHR | P16473 | 3/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | ELANE | P08246 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2740693 | 0.83 | POLB (0.45) | POLBKMT2AMEN1HDAC3HDAC4 | |
| SCHEMBL21778856 | 0.81 | POLB (0.46) | POLBKMT2AHDAC3HDAC4HDAC7 | |
| SCHEMBL7561924 | 0.81 | TSHR (0.47) | POLBKMT2AMEN1ATMHDAC3 | |
| SCHEMBL13561351 | 0.81 | HTR2A (0.46) | POLBKMT2AMEN1HDAC4HDAC7 | |
| SCHEMBL27563105 | 0.80 | POLB (0.42) | POLBKMT2AHDAC3HDAC4HDAC7 | |
| SCHEMBL434649 | 0.79 | POLB (0.52) | POLBKMT2AMEN1HDAC3HDAC4 | |
| SCHEMBL4402923 | 0.79 | POLB (0.71) | POLBKMT2AMEN1HDAC3HDAC4 | |
| SCHEMBL30341829 | 0.79 | POLB (0.71) | POLBKMT2AMEN1HDAC3HDAC4 | |
| SCHEMBL17426002 | 0.79 | POLB (0.50) | POLBKMT2AMEN1CYP1A2TSHR | |
| SCHEMBL4265489 | 0.78 | CYP2D6 (0.41) | POLBKMT2ACYP1A2TSHRCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112341359-B | Fluorenoxime ester compound, preparation method and application thereof | 常州强力电子新材料股份有限公司 | 2022-05-06 | — | — | CN | disclosed |
| CN-112341359-A | Fluorenoxime ester compound, preparation method and application thereof | 常州强力电子新材料股份有限公司 | 2021-02-09 | — | — | CN | disclosed |
| US-20170281601-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | ARDEA BIOSCIENCES, INC. | 2017-10-05 | — | — | US | disclosed |
| US-20170183333-A1 | DERIVATIVES OF N-(ARYLAMINO) SULFONAMIDES AS INHIBITORS OF MEK | ARDEA BIOSCIENCES, INC. (US) | 2017-06-29 | — | — | US | disclosed |
| US-20160221970-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | ARDEA BIOSCIENCES, INC. | 2016-08-04 | — | — | US | disclosed |
| US-20160221969-A1 | Compounds, compositions and methods of using same for modulating uric acid levels | ARDEA BIOSCIENCES, INC. | 2016-08-04 | — | — | US | disclosed |
| US-9212135-B2 | Phenylthioacetate compounds, compositions and methods of use | ARDEA BIOSCIENCES, INC. (US) | 2015-12-15 | — | — | US | disclosed |
| US-20150322006-A1 | PHENYLTHIOACETATE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | ARDEA BIOSCIENCES, INC. | 2015-11-12 | — | — | US | disclosed |
| US-20140378466-A1 | DERIVATIVES OF N-(ARYLAMINO) SULFONAMIDES AS INHIBITORS OF MEK | ARDEA BIOSCIENCES (US) | 2014-12-25 | — | — | US | disclosed |
| US-8829052-B2 | Derivatives of N-(arylamino)sulfonamides as inhibitors of MEK | ARDEA BIOSCIENCES, INC. (US) | 2014-09-09 | — | — | US | disclosed |
| US-20090197825-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | ARDEA BIOSCIENCES, INC. (US) | 2009-08-06 | — | — | US | disclosed |
| US-20090162319-A1 | REVERSE TRANSCRIPTASE INHIBITORS | ARDEA BIOSCIENCES (US) | 2009-06-25 | — | — | US | disclosed |
| US-20090082457-A1 | (S)-N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide; MEK kinase (mitogen-activated ERK-activating kinases, MAP kinase kinase); cancer, tumors, autoimmune disorders, ischemia, rheumatoid arthritis, multiple sclerosis, psoriasis, restenosis | ANDREA BIOSCIENCES, INC. (US) | 2009-03-26 | — | — | US | disclosed |
| US-20080233606-A1 | to determine activity of cytochrome P450 by monitoring appearance of metabolites that arise from enzyme-specific reactions using probe substrates for each cytochrome P450 enzyme; accuracy available with mass spectroscopy-based methods without limitations of high throughput fluorescence-based methods | HADDACH MUSTAPHA | 2008-09-25 | — | — | US | disclosed |
| US-20080227851-A1 | LAULIMALIDE AND LAULIMALIDE ANALOGS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2008-09-18 | — | — | US | disclosed |
| US-20080176871-A1 | 4-CYANOPHENYLAMINO-SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS AS HIV INHIBITORS | ARDEA BIOSCIENCES, INC. (US) | 2008-07-24 | — | — | US | disclosed |
| US-20080058340-A1 | MEK kinase (mitogen-activated ERK-activating kinases or MAP kinase kinase); cancer, tumors, infections, autoimmune disorders, stroke, ischemia, rheumatoid arthritis, multiple sclerosis, psoriasis, restenosis; 1-sulfonamido-2-(phenylamino)-4-fluorobenzene compounds | ARDEA BIOSCIENCES, INC. (US) | 2008-03-06 | — | — | US | disclosed |
| US-20080045497-A1 | SUBSTITUTED ANILINE DERIVATIVES | UCB PHARMA S.A. (BE) | 2008-02-21 | — | — | US | disclosed |
| US-20070244164-A1 | PYRIDONE SULFONAMIDES AND PYRIDONE SULFAMIDES AS MEK INHIBITORS | ARDEA BIOSCIENCES (US) | 2007-10-18 | — | — | US | disclosed |
| US-20070238710-A1 | N-ARYL-N'ALKYL SULFAMIDES AS MEK INHIBITORS | ARDEA BIOSCIENCES (US) | 2007-10-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (16 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080227851-A1 | LAULIMALIDE AND LAULIMALIDE ANALOGS | SSB, LPXN, LTA | POLB 114/4885KMT2A 4481/4885MEN1 326/4885 |
| US-20080058340-A1 | MEK kinase (mitogen-activated ERK-activating kinases or MAP kinase kinase); cancer, tumors, infections, autoimmune disorders, stroke, ischemia, rheumatoid arthritis, multiple sclerosis, psoriasis, restenosis; 1-sulfonamido-2-(phenylamino)-4-fluorobenzene compounds | BRAF, MAPK1, MAPK12 | POLB 756/4885KMT2A 1629/4885MEN1 1092/4885 |
| US-20080176871-A1 | 4-CYANOPHENYLAMINO-SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS AS HIV INHIBITORS | CYCS, DCK, NSUN2 | POLB 60/4885KMT2A 925/4885MEN1 4877/4885 |
| US-20080233606-A1 | to determine activity of cytochrome P450 by monitoring appearance of metabolites that arise from enzyme-specific reactions using probe substrates for each cytochrome P450 enzyme; accuracy available with mass spectroscopy-based methods without limitations of high throughput fluorescence-based methods | CYP2E1, CYP3A43, CYP3A4 | POLB 2088/4885KMT2A 3626/4885MEN1 4654/4885 |
| US-20170183333-A1 | DERIVATIVES OF N-(ARYLAMINO) SULFONAMIDES AS INHIBITORS OF MEK | BRAF, NRAS, MAP3K2 | POLB 2063/4885KMT2A 502/4885MEN1 1666/4885 |
| US-20070238710-A1 | N-ARYL-N'ALKYL SULFAMIDES AS MEK INHIBITORS | NRAS, BRAF, HRAS | POLB 2148/4885KMT2A 327/4885MEN1 1733/4885 |
| US-20090197825-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | XDH, PON1, GLS | POLB 1828/4885KMT2A 3006/4885MEN1 3842/4885 |
| US-20160221969-A1 | Compounds, compositions and methods of using same for modulating uric acid levels | XDH, PON1, OAT | POLB 2505/4885KMT2A 2164/4885MEN1 3374/4885 |
| US-20080045497-A1 | SUBSTITUTED ANILINE DERIVATIVES | DPM1, ERG28, IL4I1 | POLB 2192/4885KMT2A 2035/4885MEN1 552/4885 |
| US-20090162319-A1 | REVERSE TRANSCRIPTASE INHIBITORS | POLRMT, POLR1E, TYMP | POLB 12/4885KMT2A 702/4885MEN1 4828/4885 |
| US-20140378466-A1 | DERIVATIVES OF N-(ARYLAMINO) SULFONAMIDES AS INHIBITORS OF MEK | BRAF, NRAS, MAP3K2 | POLB 2063/4885KMT2A 502/4885MEN1 1666/4885 |
| US-20090082457-A1 | (S)-N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide; MEK kinase (mitogen-activated ERK-activating kinases, MAP kinase kinase); cancer, tumors, autoimmune disorders, ischemia, rheumatoid arthritis, multiple sclerosis, psoriasis, restenosis | BRAF, MAPK1, MAP2K2 | POLB 1669/4885KMT2A 1554/4885MEN1 2467/4885 |
| US-20160221970-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | XDH, PON1, GLS | POLB 1828/4885KMT2A 3006/4885MEN1 3842/4885 |
| US-20150322006-A1 | PHENYLTHIOACETATE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | PON1, NUDT1, HPRT1 | POLB 1037/4885KMT2A 1491/4885MEN1 2901/4885 |
| US-20170281601-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | XDH, PON1, GLS | POLB 1828/4885KMT2A 3006/4885MEN1 3842/4885 |
| US-20070244164-A1 | PYRIDONE SULFONAMIDES AND PYRIDONE SULFAMIDES AS MEK INHIBITORS | BRAF, PDXK, MAP3K20 | POLB 1869/4885KMT2A 836/4885MEN1 1983/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.